Favipiravir: the hidden threat of mutagenic action
Oleg P Zhirnov, Alyona I Chernyshova
Journal of microbiology, epidemiology and immunobiology, doi:10.36233/0372-9311-114
The antiviral drug favipiravir (FPV), which is a structural analogue of guanosine, undergoes chemical transformation in infected cells by cellular enzymes into a nucleotide form -favipiravir ribose triphosphate (FPV-RTP). FPV-RTP is able to bind to viral RNA-dependent RNA polymerase and integrate into the viral RNA chain, causing a significant mutagenic effect through G→A and G→U transitions in the viral RNA genome. Besides the virus inhibiting effect, the increased synthesis of mutant virions under the action of FP possess a threat of the emergence of novel threatening viral strains with high pathogenicity for humans and animals and acquired resistance to chemotherapeutic compound. There are three ways to minimize this mutagenic effect of FP. (1) Synthesis of new FPV modifications lacking the ability to integrate into the synthesized viral RNA molecule. (2) The combined use of FPV with antiviral chemotherapeutic drugs of a different mechanism of action directed at various viral and/or host cell targets. (3) Permanent application of high therapeutic doses of FPV under the strict medical control to enhance the lethal mutagenic effect on an infectious virus in the recipient organism to prevent the multiplication of its mutant forms.
Author contribution. Аll authors made a substantial contribution to the conception of the work, acquisition, analysis, interpretation of data for the work, drafting and revising the work, final approval of the version to be published.
References
Abdelnabi, Morais, Leyssen, Imbert, Beaucourt et al., Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase, J. Virol,
doi:10.1128/jvi.00487-17Alyona, Chernyshova -Junior, Researcher, None
Arias, Thorne, Goodfellow, Favipiravir elicit antiviral mutagenesis during virus replication in vivo, eLife,
doi:10.7554/elife.03679Baranovich, Wong, Armstrong, Marjuki, Webby et al., T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro, J. Virol,
doi:10.1128/jvi.02346-12Baz, Carbonneau, Rhéaume, Cavanagh, Boivin, Combination therapy with Oseltamivir and Favipiravir delays mortality but does not prevent Oseltamivir resistance in immunodeficient mice infected with pandemic A(H1N1) influenza virus, Viruses,
doi:10.3390/v10110610Beigel, Bao, Beeler, Manosuthi, Slandzicki et al., A randomized double-blind phase 2 study of combination antivirals for the treatment of influenza, Lancet,
doi:10.1016/S1473-3099(17)30476-0Bixler, Bocan, Wells, Wetzel, Van Tongeren et al., Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus, Antiviral Res,
doi:10.1016/j.antiviral.2017.12.020Cai, Yang, Liu, Chen, Shu et al., Experimental treatment with Favipiravir for COVID-19: An open-label control study, Engineering,
doi:10.1016/j.eng.2020.03.007Du, Chen, Response to "Dose rationale for Favipiravir use in patients infected with SARS-CoV-2, Clin. Pharmacol. Ther,
doi:10.1002/cpt.1878Dunning, Baillie, Cao, Hayden, Antiviral combinations for severe influenza, Lancet Infect. Dis,
doi:10.1016/S1473-3099Eloy, Solas, Touret, Mentré, Malvy et al., Dose rationale for Favipiravir use in patients infected with SARS-CoV-2, Clin. Pharmacol. Ther,
doi:10.1002/cpt.1877Ferron, Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA, Proc. Natl. Acad. Sci,
doi:10.1073/pnas.1718806115Furuta, Egawa, Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing both, European Patent Office WO
Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc. Jpn Acad. Ser. B Phys. Biol. Sci,
doi:10.2183/pjab.93.027Furuta, Takahashi, Kuno-Maekawa, Sangawa, Uehara et al., Mechanism of action of T-705 against influenza virus, Antimicrob. Agents Chemother,
doi:10.1128/AAC.49.3.981-986.2005Goldhill, Velthuis, Fletcher, Langat, Zambon et al., The mechanism of resistance to Favipiravir in influenza, Proc. Natl Acad. Sci,
doi:10.1073/pnas.1811345115Grande-Pérez, Lazaro, Lowenstein, Domingo, Manrubia, Suppression of viral infectivity through lethal defection, Proc. Natl Acad. Sci,
doi:10.1073/pnas.0408871102Guedj, Piorkowski, Jacquot, Madelain, Nguyen et al., Antiviral efficacy of Favipiravir against Ebo la virus: A translational study in cynomolgus macaques, PLoS Med,
doi:10.1371/journal.pmed.1002535Hurt, Ison, Hayden, Hay, Second isirv antiviral group conference: overview. Influenza Other, Respir. Viru ses,
doi:10.1111/irv.12207Ilyushina, Bovin, Webster, Govorkova, Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants, Antiviral Res,
doi:10.1016/j.antiviral.2006.01.012Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for treatment of patients with moderate COVID-19: Interim results of a phase II/III multicenter randomized clinical trial, Clin. Infect. Dis,
doi:10.1093/cid/ciaa1176Jordan, Stevens, Deval, Nucleosides for the treatment of respiratory RNA virus infections, Antivir. Chem. Chemother,
doi:10.1177/2040206618764483Li, Yang, Liu, Yang, Zhao et al., Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019, Pharmacol. Res,
doi:10.1016/j.phrs.2020.105036Lu, Hardes, Dahms, Böttcher-Friebertshäuser, Steinmetzer et al., Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells, Antiviral Res,
doi:10.1016/j.antiviral.2015.05.006Naesens, Guddat, Keough, Van Kuilenburg, Meijer et al., Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir), Mol. Pharmacol,
doi:10.1124/mol.113.087247Neogi, Hill, Ambikan, Heng, Quinn et al., Feasibility of known RNA polymerase inhibitors as anti-SARS-CoV-2 drugs, Pathogens,
doi:10.3390/pathogens9050320Ortega, Zambrano, Jastrzebska, Liprandi, Rangel et al., Understanding severe acute respiratory syndrome coronavirus 2 replication to design efficient drug combination therapies, Intervirology,
doi:10.1159/000512141Perales, Gallego, De Ávila, Soria, Gregori et al., The increasing impact of lethal mutagenesis of viruses, Future Med. Chem,
doi:10.4155/fmc-2018-0457Perales, Mateo, Mateu, Domingo, Insights into RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants, J. Mol. Biol,
doi:10.1016/j.jmb.2007.03.074Pilkington, Pepperrell, Hill, A review of the safety of favipiravir -a potential treatment in the COVID-19 pandemic?, J. Virus Erad,
doi:10.1016/s2055-6640(20)30016-9Sada, Saraya, Ishii, Okayama, Hayashi et al., Detailed molecular interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza virus polymerases in silico, Microorganisms,
doi:10.3390/microorganisms8101610Sangawa, Komeno, Nishikawa, Yoshida, Takahashi et al., Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase, Antimicrob. Agents Chemother,
doi:10.1128/aac.00649-13Shannon, Selisko, Le, Huchting, Touret et al., Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in ЖУРНАЛ МИКРОБИОЛОГИИ
Smee, Hurst, Egawa, Takahashi, Kadota et al., Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J. Antimicrob, Chemother,
doi:10.1093/jac/dkp274Smith, Rajwanshi, Kim, Deval, The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) ribofuranosyl 5'-triphosphate towards influenza A virus polymerase, PLoS One,
doi:10.1371/journal.pone.0068347Tsai, Lu, Bau, Chiu, Yen et al., Approaches towards fighting the COVID-19 pandemic (Review), Int. J. Mol. Med,
doi:10.3892/ijmm.2020.4794Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell. Res,
doi:10.1038/s41422-020-0282-0Zhirnov -D. Sci ; Prof, Corr, Information about the authors Oleg
Zhirnov, High protection of animals lethally infected with influenza virus by aprotinin-rimantadine combination, J. Med. Virol,
doi:10.1002/jmv.1890210208Авторов, Все авторы внесли существенный вклад в проведение поисково-аналитической работы и подготовку статьи, прочли и одобрили финальную версию до публикации, Статья поступила в редакцию
Алёна Игоревна -М, Русско-немецкой академии медико-социальных и биотехнологических наук
{ 'indexed': {'date-parts': [[2022, 3, 31]], 'date-time': '2022-03-31T14:51:34Z', 'timestamp': 1648738294054},
'reference-count': 44,
'publisher': 'Central Research Institute for Epidemiology',
'issue': '2',
'license': [ { 'start': { 'date-parts': [[2021, 5, 5]],
'date-time': '2021-05-05T00:00:00Z',
'timestamp': 1620172800000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://microbiol.elpub.ru/jour/about/editorialPolicies#openAccessPolicy'}],
'content-domain': {'domain': ['microbiol.elpub.ru'], 'crossmark-restriction': True},
'abstract': '<jats:p>\xa0</jats:p><jats:p>The antiviral drug favipiravir (FVP), which is a structural '
'analogue of guanosine, undergoes chemical transformation in infected cells by cellular '
'enzymes into a nucleotide form — favipiravir ribose triphosphate (FVPRTP). FVP-RTP is able to '
'bind to viral RNA-dependent RNA polymerase and integrate into the viral RNA chain, causing a '
'significant mutagenic effect through G→A and С→U transitions in the viral RNA genome. Besides '
'the virus inhibiting effect, the increased synthesis of mutant virions under the action of '
'FPV possess a threat of the emergence of novel threatening viral strains with high '
'pathogenicity for humans and animals and acquired resistance to chemotherapeutic compound. '
'There are three ways to minimize this mutagenic effect of FP. (1) Synthesis of new FPV '
'modifications lacking the ability to integrate into the synthesized viral RNA molecule. (2) '
'The combined use of FPV with antiviral chemotherapeutic drugs of a different mechanism of '
'action directed at various viral and/or host cell targets. (3) Permanent application of high '
'therapeutic doses of FPV under the strict medical control to enhance the lethal mutagenic '
'effect on an infectious virus in the recipient organism to prevent the multiplication of its '
'mutant forms.</jats:p>',
'DOI': '10.36233/0372-9311-114',
'type': 'journal-article',
'created': {'date-parts': [[2021, 5, 5]], 'date-time': '2021-05-05T07:44:12Z', 'timestamp': 1620200652000},
'page': '213-220',
'update-policy': 'http://dx.doi.org/10.36233/0372-9311-crossmark',
'source': 'Crossref',
'is-referenced-by-count': 3,
'title': 'Favipiravir: the hidden threat of mutagenic action',
'prefix': '10.36233',
'volume': '98',
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-3192-8405',
'authenticated-orcid': True,
'given': 'O. P.',
'family': 'Zhirnov',
'sequence': 'first',
'affiliation': [ { 'name': 'The Russian-German Academy of Medico-Social and Biotechnological '
'Sciences;\r\n'
'The D.I. Ivanovsky Institute of Virology, The N.F. Gamaleya '
'National Research Center of Epidemiology and Microbiology'}]},
{ 'ORCID': 'http://orcid.org/0000-0003-1290-4042',
'authenticated-orcid': True,
'given': 'A. I.',
'family': 'Chernyshova',
'sequence': 'additional',
'affiliation': [ { 'name': 'The D.I. Ivanovsky Institute of Virology, The N.F. Gamaleya '
'National Research Center of Epidemiology and Microbiology;\r\n'
'The I.M. Sechenov First Moscow State Medical University '
'(Sechenov University)'}]}],
'member': '22004',
'published-online': {'date-parts': [[2021, 5, 5]]},
'reference': [ { 'key': 'ref1',
'doi-asserted-by': 'crossref',
'unstructured': 'Zhirnov O.P. Molecular targets in the chemotherapy of coronavirus '
'infection. Biochemistry (Mosc). 2020; 85(5): 523–30. '
'https://doi.org/10.1134/S0006297920050016',
'DOI': '10.1134/S0006297920050016'},
{ 'key': 'ref2',
'doi-asserted-by': 'crossref',
'unstructured': 'Tsai S.C., Lu C.C., Bau D.T., Chiu Y.J., Yen Y.T., Hsu Y.M., et al. '
'Approaches towards fighting the COVID 19 pandemic (Review). Int. J. Mol. '
'Med. 2020; 47(1): 3–22. https://doi.org/10.3892/ijmm.2020.4794',
'DOI': '10.3892/ijmm.2020.4794'},
{ 'key': 'ref3',
'doi-asserted-by': 'crossref',
'unstructured': 'Furuta Y., Gowen B.B., Takahashi K., Shiraki K., Smee D.F., Barnard D.L. '
'Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral '
'Res. 2013; 100(2): 446–54. '
'https://doi.org/10.1016/j.antiviral.2013.09.015',
'DOI': '10.1016/j.antiviral.2013.09.015'},
{ 'key': 'ref4',
'doi-asserted-by': 'crossref',
'unstructured': 'Furuta Y., Komeno T., Nakamura T. Favipiravir (T-705), a broad spectrum '
'inhibitor of viral RNA polymerase. Proc. Jpn Acad. Ser. B Phys. Biol. '
'Sci. 2017; 93(7): 449–63. https://doi.org/10.2183/pjab.93.027',
'DOI': '10.2183/pjab.93.027'},
{ 'key': 'ref5',
'unstructured': 'Furuta Y., Egawa H. Nitrogenous heterocyclic carboxamide derivatives or '
'salts thereof and antiviral agents containing both. European Patent '
'Office WO, 00/10569 (JP25044198 application 20.08.1998). WO2000010569A1; '
'2000.'},
{ 'key': 'ref6',
'doi-asserted-by': 'crossref',
'unstructured': 'Shiraki K., Daikoku T. Favipiravir, an anti-influenza drug against '
'life-threatening RNA virus infections. Pharmacol Ther. 2020; 209: '
'107512. https://doi.org/10.1016/j.pharmthera.2020.107512',
'DOI': '10.1016/j.pharmthera.2020.107512'},
{ 'key': 'ref7',
'doi-asserted-by': 'crossref',
'unstructured': 'Pilkington V., Pepperrell T., Hill A. A review of the safety of '
'favipiravir – a potential treatment in the COVID-19 pandemic? J. Virus '
'Erad. 2020; 6(2): 45–51. https://doi.org/10.1016/s2055-6640(20)30016-9',
'DOI': '10.1016/S2055-6640(20)30016-9'},
{ 'key': 'ref8',
'doi-asserted-by': 'crossref',
'unstructured': 'Abdelnabi R., Morais A.T.S., Leyssen P., Imbert I., Beaucourt S., Blanc '
'H., et al. Understanding the Mechanism of the Broad-Spectrum Antiviral '
'Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral '
'Polymerase. J. Virol. 2017; 91(12): e00487–17. '
'https://doi.org/10.1128/jvi.00487-17',
'DOI': '10.1128/JVI.00487-17'},
{ 'key': 'ref9',
'doi-asserted-by': 'crossref',
'unstructured': 'Jordan P.C., Stevens S.K., Deval J. Nucleosides for the treatment of '
'respiratory RNA virus infections. Antivir. Chem. Chemother. 2018; 26: '
'2040206618764483. https://doi.org/10.1177/2040206618764483',
'DOI': '10.1177/2040206618764483'},
{ 'key': 'ref10',
'doi-asserted-by': 'crossref',
'unstructured': 'Neogi U., Hill K.J., Ambikan A.T., Heng X., Quinn T.P., Byrareddy S.N., '
'et al. Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 '
'Drugs. Pathogens. 2020; 9(5): 320. '
'https://doi.org/10.3390/pathogens9050320',
'DOI': '10.3390/pathogens9050320'},
{ 'key': 'ref11',
'doi-asserted-by': 'crossref',
'unstructured': 'Delang L., Abdelnabi R., Neyts J. Favipiravir as a potential '
'countermeasure against neglected and emerging RNA viruses. Antiviral '
'Res. 2018; 153: 85–94. https://doi.org/10.1016/j.antiviral.2018.03.003',
'DOI': '10.1016/j.antiviral.2018.03.003'},
{ 'key': 'ref12',
'doi-asserted-by': 'crossref',
'unstructured': 'Sada M., Saraya T., Ishii H., Okayama K., Hayashi Y., Tsugawa T., et al. '
'Detailed molecular interactions of Favipiravir with SARS-CoV-2, '
'SARS-CoV, MERS-CoV, and influenza virus polymerases in silico. '
'Microorganisms. 2020; 8(10): 1610. '
'https://doi.org/10.3390/microorganisms8101610',
'DOI': '10.3390/microorganisms8101610'},
{ 'key': 'ref13',
'doi-asserted-by': 'crossref',
'unstructured': 'Naesens L., Guddat L.W., Keough D.T., van Kuilenburg A.B., Meijer J., '
'Vande Voorde J., et al. Role of human hypoxanthine guanine '
'phosphoribosyltransferase in activation of the antiviral agent T-705 '
'(favipiravir). Mol. Pharmacol. 2013; 84(4): 615–29. '
'https://doi.org/10.1124/mol.113.087247',
'DOI': '10.1124/mol.113.087247'},
{ 'key': 'ref14',
'doi-asserted-by': 'crossref',
'unstructured': 'Smee D.F., Hurst B.L., Egawa H., Takahashi K., Kadota T., Furuta Y. '
'Intracellular metabolism of favipiravir (T-705) in uninfected and '
'influenza A (H5N1) virus-infected cells. J. Antimicrob. Chemother. 2009; '
'64(4): 741–6. https://doi.org/10.1093/jac/dkp274',
'DOI': '10.1093/jac/dkp274'},
{ 'key': 'ref15',
'doi-asserted-by': 'crossref',
'unstructured': 'Bixler S.L., Bocan T.M., Wells J., Wetzel K.S., Van Tongeren S.A., Garza '
'N.L., et al. Intracellular conversion and in vivo dose response of '
'favipiravir (T-705) in rodents infected with Ebola virus. Antiviral Res. '
'2018; 151: 50–4. https://doi.org/10.1016/j.antiviral.2017.12.020',
'DOI': '10.1016/j.antiviral.2017.12.020'},
{ 'key': 'ref16',
'doi-asserted-by': 'crossref',
'unstructured': 'Baranovich T., Wong S.S., Armstrong J., Marjuki H., Webby R.J., Webster '
'R.G., et al. T-705 (favipiravir) induces lethal mutagenesis in influenza '
'A H1N1 viruses in vitro. J. Virol. 2013; 87(7): 3741–51. '
'https://doi.org/10.1128/jvi.02346-12',
'DOI': '10.1128/JVI.02346-12'},
{ 'key': 'ref17',
'doi-asserted-by': 'crossref',
'unstructured': 'Arias A., Thorne L., Goodfellow I. Favipiravir elicit antiviral '
'mutagenesis during virus replication in vivo. eLife. 2014; 3: e03679. '
'https://doi.org/10.7554/elife.03679',
'DOI': '10.7554/eLife.03679'},
{ 'key': 'ref18',
'doi-asserted-by': 'crossref',
'unstructured': 'Sangawa H., Komeno T., Nishikawa H., Yoshida A., Takahashi K., Nomura '
'N., et al. Mechanism of action of T-705 ribosyl triphosphate against '
'influenza virus RNA polymerase. Antimicrob. Agents Chemother. 2013; '
'57(11): 5202–8. https://doi.org/10.1128/aac.00649-13',
'DOI': '10.1128/AAC.00649-13'},
{ 'key': 'ref19',
'doi-asserted-by': 'crossref',
'unstructured': 'Jin Z., Smith L.K., Rajwanshi V.K., Kim B., Deval J. The ambiguous '
'base-pairing and high substrate efficiency of T-705 (Favipiravir) '
'ribofuranosyl 5’-triphosphate towards influenza A virus polymerase. PLoS '
'One. 2013; 8(7): e68347. https://doi.org/10.1371/journal.pone.0068347',
'DOI': '10.1371/journal.pone.0068347'},
{ 'key': 'ref20',
'doi-asserted-by': 'crossref',
'unstructured': 'de Ávila A.I., Gallego I., Soria M.E., Gregori J., Quer J., Esteban '
'J.I., et al. Lethal mutagenesis of hepatitis C virus induced by '
'Favipiravir. PLoS One. 2016; 11(10): e0164691. '
'https://doi.org/10.1371/journal.pone.0164691',
'DOI': '10.1371/journal.pone.0164691'},
{ 'key': 'ref21',
'doi-asserted-by': 'crossref',
'unstructured': 'Guedj J., Piorkowski G., Jacquot F., Madelain V., Nguyen T.H.T., '
'Rodallec A., et al. Antiviral efficacy of Favipiravir against Ebola '
'virus: A translational study in cynomolgus macaques. PLoS Med. 2018; '
'15(3): e1002535. https://doi.org/10.1371/journal.pmed.1002535',
'DOI': '10.1371/journal.pmed.1002535'},
{ 'key': 'ref22',
'doi-asserted-by': 'crossref',
'unstructured': 'Goldhill D.H., te Velthuis A.J.W., Fletcher R.A., Langat P., Zambon M., '
'Lackenby A., et al. The mechanism of resistance to Favipiravir in '
'influenza. Proc. Natl Acad. Sci. USA. 2018; 115(45): 11613–8. '
'https://doi.org/10.1073/pnas.1811345115',
'DOI': '10.1073/pnas.1811345115'},
{ 'key': 'ref23',
'doi-asserted-by': 'crossref',
'unstructured': 'Shannon A., Selisko B., Le N.T., Huchting J., Touret F., Piorkowski G., '
'et al. Rapid incorporation of Favipiravir by the fast and permissive '
'viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. '
'Nat. Commun. 2020; 11(1): 4682. '
'https://doi.org/10.1038/s41467-020-18463-z',
'DOI': '10.1038/s41467-020-18463-z'},
{ 'key': 'ref24',
'doi-asserted-by': 'crossref',
'unstructured': 'Grande-Pérez A., Lazaro E., Lowenstein P., Domingo E., Manrubia S.C. '
'Suppression of viral infectivity through lethal defection. Proc. Natl '
'Acad. Sci. USA. 2005; 102(12): 4448–52. '
'https://doi.org/10.1073/pnas.0408871102',
'DOI': '10.1073/pnas.0408871102'},
{ 'key': 'ref25',
'doi-asserted-by': 'crossref',
'unstructured': 'Perales C., Mateo R., Mateu M.G., Domingo E. Insights into RNA virus '
'mutant spectrum and lethal mutagenesis events: replicative interference '
'and complementation by multiple point mutants. J. Mol. Biol. 2007; '
'369(4): 985–1000. https://doi.org/10.1016/j.jmb.2007.03.074',
'DOI': '10.1016/j.jmb.2007.03.074'},
{ 'key': 'ref26',
'doi-asserted-by': 'crossref',
'unstructured': 'Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., et al. Remdesivir and '
'chloroquine effectively inhibit the recently emerged novel coronavirus '
'(2019-nCoV) in vitro. Cell. Res. 2020; 30: 269–71. '
'https://doi.org/10.1038/s41422-020-0282-0',
'DOI': '10.1038/s41422-020-0282-0'},
{ 'key': 'ref27',
'doi-asserted-by': 'crossref',
'unstructured': 'Cai Q., Yang M., Liu D., Chen J., Shu D., Xia J., et al. Experimental '
'treatment with Favipiravir for COVID-19: An open-label control study. '
'Engineering (Beijing). 2020; 6(10): 1192–8. '
'https://doi.org/10.1016/j.eng.2020.03.007',
'DOI': '10.1016/j.eng.2020.03.007'},
{ 'key': 'ref28',
'doi-asserted-by': 'crossref',
'unstructured': 'Joshi S., Parkar J., Ansari A., Vora A., Talwar D., Tiwaskar M., et al. '
'Role of Favipiravir in the treatment of COVID-19. Int. J. Infect. Dis. '
'2020; 102: 501–8. https://doi.org/10.1016/j.ijid.2020.10.069',
'DOI': '10.1016/j.ijid.2020.10.069'},
{ 'key': 'ref29',
'doi-asserted-by': 'crossref',
'unstructured': 'Ivashchenko A.A., Dmitriev K.A., Vostokova N.V., Azarova V.N., Blinow '
'A.A., Egorova A.N., et al. AVIFAVIR for treatment of patients with '
'moderate COVID-19: Interim results of a phase II/III multicenter '
'randomized clinical trial. Clin. Infect. Dis. 2020; ciaa1176. '
'https://doi.org/10.1093/cid/ciaa1176',
'DOI': '10.1093/cid/ciaa1176'},
{ 'key': 'ref30',
'doi-asserted-by': 'crossref',
'unstructured': 'Eloy P., Solas C., Touret F., Mentré F., Malvy D., de Lamballerie X., et '
'al. Dose rationale for Favipiravir use in patients infected with '
'SARS-CoV-2. Clin. Pharmacol. Ther. 2020; 108(2): 188. '
'https://doi.org/10.1002/cpt.1877',
'DOI': '10.1002/cpt.1877'},
{ 'key': 'ref31',
'doi-asserted-by': 'crossref',
'unstructured': 'Perales C., Gallego I., de ́Avila A.I., Soria M.E., Gregori J., Quer J., '
'et al. The increasing impact of lethal mutagenesis of viruses. Future '
'Med. Chem. 2019; 11(13): 1645–57. https://doi.org/10.4155/fmc-2018-0457',
'DOI': '10.4155/fmc-2018-0457'},
{ 'key': 'ref32',
'doi-asserted-by': 'crossref',
'unstructured': 'Li G., De Clercq E. Therapeutic options for the 2019 novel coronavirus '
'(2019-nCoV). Nat. Rev. Drug Discov. 2020; 19(3): 149–50. '
'https://doi.org/10.1038/d41573-020-00016-0',
'DOI': '10.1038/d41573-020-00016-0'},
{ 'key': 'ref33',
'doi-asserted-by': 'crossref',
'unstructured': 'Ferron F. Structural and molecular basis of mismatch correction and '
'ribavirin excision from coronavirus RNA. Proc. Natl. Acad. Sci. USA. '
'2018; 115(2): E162–71. https://doi.org/10.1073/pnas.1718806115',
'DOI': '10.1073/pnas.1718806115'},
{ 'key': 'ref34',
'doi-asserted-by': 'crossref',
'unstructured': 'Ilyushina N.A., Bovin N.V., Webster R.G., Govorkova E.A. Combination '
'chemotherapy, a potential strategy for reducing the emergence of '
'drug-resistant influenza A variants. Antiviral Res. 2006; 70(3): 121–31. '
'https://doi.org/10.1016/j.antiviral.2006.01.012',
'DOI': '10.1016/j.antiviral.2006.01.012'},
{ 'key': 'ref35',
'doi-asserted-by': 'crossref',
'unstructured': 'Lu Y., Hardes K., Dahms S.O., Böttcher-Friebertshäuser E., Steinmetzer '
'T., Than M.E., et al. Peptidomimetic furin inhibitor MI-701 in '
'combination with oseltamivir and ribavirin efficiently blocks '
'propagation of highly pathogenic avian influenza viruses and delays high '
'level oseltamivir resistance in MDCK cells. Antiviral Res. 2015; 120: '
'89–100. https://doi.org/10.1016/j.antiviral.2015.05.006',
'DOI': '10.1016/j.antiviral.2015.05.006'},
{ 'key': 'ref36',
'doi-asserted-by': 'crossref',
'unstructured': 'Baz M., Carbonneau J., Rhéaume C., Cavanagh M.H., Boivin G. Combination '
'therapy with Oseltamivir and Favipiravir delays mortality but does not '
'prevent Oseltamivir resistance in immunodeficient mice infected with '
'pandemic A(H1N1) influenza virus. Viruses. 2018; 10(11): 610. '
'https://doi.org/10.3390/v10110610',
'DOI': '10.3390/v10110610'},
{ 'key': 'ref37',
'doi-asserted-by': 'crossref',
'unstructured': 'Beigel J.H., Bao Y., Beeler J., Manosuthi W., Slandzicki A., Dar S.M., '
'et al. A randomized double-blind phase 2 study of combination antivirals '
'for the treatment of influenza. Lancet Infect. Dis. 2017; 17: 1255–65. '
'https://doi.org/10.1016/S1473-3099(17)30476-0',
'DOI': '10.1016/S1473-3099(17)30476-0'},
{ 'key': 'ref38',
'doi-asserted-by': 'crossref',
'unstructured': 'Hurt A.C., Ison M.G., Hayden F.G., Hay A.J. Second isirv antiviral group '
'conference: overview. Influenza Other Respir. Viruses. 2013; 7(Suppl. '
'3): 1–7. https://doi.org/10.1111/irv.12207',
'DOI': '10.1111/irv.12207'},
{ 'key': 'ref39',
'doi-asserted-by': 'crossref',
'unstructured': 'Dunning J., Baillie J.K., Cao B., Hayden F.G. Antiviral combinations for '
'severe influenza. Lancet Infect. Dis. 2014; 14(12): 1259–70. '
'https://doi.org/10.1016/S1473-3099(14)70821-7',
'DOI': '10.1016/S1473-3099(14)70821-7'},
{ 'key': 'ref40',
'doi-asserted-by': 'crossref',
'unstructured': 'Li X., Yang Y., Liu L., Yang X., Zhao X., Li Y., et al. Effect of '
'combination antiviral therapy on hematological profiles in 151 adults '
'hospitalized with severe coronavirus disease 2019. Pharmacol. Res. 2020; '
'160: 105036. https://doi.org/10.1016/j.phrs.2020.105036',
'DOI': '10.1016/j.phrs.2020.105036'},
{ 'key': 'ref41',
'doi-asserted-by': 'crossref',
'unstructured': 'Ortega J.T., Zambrano J.L., Jastrzebska B., Liprandi F., Rangel H.R., '
'Pujol F.H. Understanding severe acute respiratory syndrome coronavirus 2 '
'replication to design efficient drug combination therapies. '
'Intervirology. 2020; 63(1-6): 2–9. https://doi.org/10.1159/000512141',
'DOI': '10.1159/000512141'},
{ 'key': 'ref42',
'doi-asserted-by': 'crossref',
'unstructured': 'Zhirnov O.P. High protection of animals lethally infected with influenza '
'virus by aprotinin-rimantadine combination. J. Med. Virol. 1987; 21(2): '
'161–7. https://doi.org/10.1002/jmv.1890210208',
'DOI': '10.1002/jmv.1890210208'},
{ 'key': 'ref43',
'doi-asserted-by': 'crossref',
'unstructured': 'Furuta Y., Takahashi K., Kuno-Maekawa M., Sangawa H., Uehara S., Kozaki '
'K., et al. Mechanism of action of T-705 against influenza virus. '
'Antimicrob. Agents Chemother. 2005; 49(3): 981–6. '
'https://doi.org/10.1128/AAC.49.3.981-986.2005',
'DOI': '10.1128/AAC.49.3.981-986.2005'},
{ 'key': 'ref44',
'doi-asserted-by': 'crossref',
'unstructured': 'Du Y.X., Chen X.P. Response to “Dose rationale for Favipiravir use in '
'patients infected with SARS-CoV-2”. Clin. Pharmacol. Ther. 2020; 108(2): '
'190. https://doi.org/10.1002/cpt.1878',
'DOI': '10.1002/cpt.1878'}],
'container-title': 'Journal of microbiology, epidemiology and immunobiology',
'original-title': [],
'link': [ { 'URL': 'https://microbiol.elpub.ru/jour/article/viewFile/1005/590',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://microbiol.elpub.ru/jour/article/viewFile/1005/598',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'text-mining'}],
'deposited': { 'date-parts': [[2021, 5, 5]],
'date-time': '2021-05-05T07:45:22Z',
'timestamp': 1620200722000},
'score': 1,
'resource': {'primary': {'URL': 'https://microbiol.elpub.ru/jour/article/view/1005'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021, 5, 5]]},
'references-count': 44,
'journal-issue': {'issue': '2', 'published-online': {'date-parts': [[2021, 5, 5]]}},
'URL': 'http://dx.doi.org/10.36233/0372-9311-114',
'relation': {},
'ISSN': ['2686-7613', '0372-9311'],
'subject': ['General Medicine'],
'container-title-short': 'Zhurnal mikrobiologii, èpidemiologii i immunobiologii',
'published': {'date-parts': [[2021, 5, 5]]}}
